Research Reports | Market Assessment
November 2017

Alzheimer’s Disease | Access and Reimbursement | EU5 | 2017

Alzheimer’s disease (AD) is a chronic neurodegenerative condition widely recognized as a global health crisis; as the general population ages and AD prevalence grows, the need for drugs to treat, delay, or stop the disease is paramount. While current therapies used to treat AD are generically available in Europe, the next five years look set to bring several premium-priced new brands addressing the cognitive as well as the behavioral symptoms of AD. This research examines the current impact of payer policy on prescribing and probes how neurologists and cost-conscious European payers will react to novel agents that, while innovative, will drive up healthcare costs considerably.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports